TempraMed Targets a US$30 Billion Market in Medication Protection

• TempraMed’s FDA-registered products address a global base of more than 160 million users who rely on temperature-sensitive injectable medications, translating into an estimated US$30 billion market opportunity.
• The company has already sold over 120,000 units and is guiding toward roughly US$19 million in revenue in 2026 with marketing of three additional products and as retail distribution and payer adoption of the company’s portfolio of products is expected to scale.
• Among the new products, the launch of VIVI Cap Smart adds a connected data layer that tracks injection timing and dosage, opening the door to recurring software revenue increasing long-term customer value and opens new corporate strategic cooperation.

“This isn’t a proof-of-concept story. It’s a real business built on proven technology and clear demand, helping people who rely on daily injectable medications manage their lives with more confidence.”
— Julia Becker, TempraMed’s VP of Capital Markets

As healthcare systems grapple with rising chronic disease, soaring drug costs, and a growing focus on patient outcomes, investors are paying closer attention to practical technologies that solve everyday problems at scale.

That was the backdrop at the recent AlphaNorth Capital Event in the Bahamas, where TempraMed Technologies Ltd. (CSE: VIVI | FSE: 9DY), drew interest as a healthcare company that has already moved past the concept stage and into execution.

With FDA-registered products already in the market, more than 120,000 units sold, and revenue guidance of roughly US$19 million in 2026, TempraMed is entering a scale-up phase in a global market that continues to expand as more patients rely on injectable therapies.

“This isn’t a company trying to prove whether the technology works,” said Julia Becker, VP Capital Markets at TempraMed. “The products are approved, they’re being used, and they’re already accepted by major payers. The discussion now is about scale.”

More than 160 million people worldwide depend on temperature-sensitive injectable medications, including insulin, GLP-1 therapies, epinephrine, and biologics. Once those drugs leave the pharmacy, however, control largely disappears.

Medications are left in cars, backpacks, beach bags, or improvised coolers, often exposed to heat or freezing that can quietly degrade effectiveness. In many cases, patients have no way of knowing whether their medication is still working as intended.

Industry data referenced by the company suggests this patient base represents a total addressable market of roughly US$30 billion. Separately, more than US$35 billion worth of medication is wasted globally each year due to temperature excursions across manufacturing, logistics, and storage, a figure that still understates losses at the patient level.

“We’re focused on what happens after the pharmacy,” Becker said. “That last mile is where medication integrity often breaks down, and it’s where there has historically been very little protection.”

TempraMed’s answer is a line of passive, reusable devices that protect medication automatically providing years of 24/7/365 thermal protection without electrical charging, ice packs, or extra steps for patients.

TempraMed’s flagship product, VIVI Cap, replaces the standard cap on insulin and GLP-1 injection pens with a reusable protective device cleared for long-term use. The platform has expanded to include VIVI Epi for epinephrine auto-injectors and VIVI Med for medication vials, enzyme strips, and biologics.

All of the products are built on the same proprietary hassle free thermal-control architecture, allowing the company to move into new injectable categories without rebuilding its core technology.

“That platform approach really matters,” Becker said. “It lets us expand without taking on the cost and risk of starting from scratch each time.”

The products are already sold through major U.S. retailers and healthcare distributors, including CVS, Walgreens, Walmart, McKesson, and Target. More importantly, TempraMed has secured listings with major U.S. payers, including Humana and Optum.

“In healthcare, payer acceptance is a real gatekeeper,” Becker said. “You can have a strong product, but if payers don’t recognize it, scale becomes very difficult. We’ve already crossed that hurdle.” Recently the company received positive response on its payer reimbursement model which demonstrates significant return on investment for medical payer coverage. This validation is expected to support the company’s path towards having a payer pilot program for securing reimbursement. 

In December 2025, TempraMed launched VIVI Cap Smart, adding a connected digital layer to its hardware platform.

The smart device records injection timing and dosage and allows that information to be shared with healthcare providers. From a business standpoint, it introduces a subscription component, estimated at roughly US$60 per year per smart device.

“This changes the economics,” Becker said. “Instead of relying only on replacing devices every few years, we can build recurring revenue on top of something people already use every day.”

The connected layer also strengthens TempraMed’s relevance to payers and healthcare systems focused on adherence, outcomes, and remote patient monitoring.

TempraMed generated approximately US$2.3 million in revenue in 2024 and is guiding toward roughly US$19 million in revenue in 2026 as distribution expands and payer adoption increases.

Gross margins are estimated at around 60%, with management targeting cash-flow breakeven during 2026. Manufacturing capacity currently supports up to one million units per year, equivalent to roughly US$70 million in annual product sales.

“That capacity gives us room to grow without constantly raising capital just to meet demand,” Becker said. “It lets us stay focused on execution.”

The balance sheet was strengthened through a CAD$7.4 million oversubscribed public financing in September 2025, followed by a fully subscribed CAD$2.5 million financing in January 2026.

A Top Pick in The Bahamas

CSE: VIVI | FSE: 9DY

1. As of market close on Friday, February 6, 2026.
2. As of market open on Monday, January 19, 2026 after being selected as a Top Pick at the CEM AlphaNorth Capital Event.

Following its Top Pick recognition in the Bahamas, TempraMed VP of Capital Markets Julia Becker spoke with us about how the company is thinking about execution, scale, and what comes next.

What makes TempraMed different from other medical device companies?

“We are solving a real, everyday problem that already affects millions of patients. Temperature-sensitive medications can lose effectiveness if they are exposed to heat or freezing once they leave the pharmacy. Our devices protect medication automatically, without need for charging or extra steps. TempraMed’s products are FDA-registered and protected by eight global patents, with coverage extending more than 20 years. Just as important, the devices are already accepted by major U.S. payers, including Humana and Optum, without direct substitutes. That puts us well past the concept stage.”

How does the shift to connected devices change the financial profile, and how much runway does the company have to scale?

“The launch of VIVI Cap Smart changes the revenue mix by adding subscription software on top of durable hardware. Instead of relying only on device replacement every few years, TempraMed can generate recurring revenue tied to data logging, adherence, and provider connectivity, which improves customer lifetime value and margin quality. At the same time, the company already has manufacturing capacity to support up to one million units annually, or roughly US$70 million in product sales. With gross margins around 60% and cash-flow breakeven expected in 2026, the focus shifts from adding capacity to executing on distribution, payer expansion, and subscription adoption.”

What should investors be watching most closely over the next year?

“Investors should focus on our execution. That means getting broader U.S. payer coverage, stronger uptake of our smart devices within the existing customer base, and continued expansion of distribution while protecting margins. The technology is already proven. The next step is delivering steady growth and building a visible, recurring software revenue stream.”

Our View

• With FDA-registered products, payer acceptance, and meaningful unit sales already in place, the company has cleared several of the execution hurdles that typically derail early healthcare companies. For investors, that shifts the risk profile away from technology validation and toward scale.
• The launch of VIVI Cap Smart introduces recurring software revenue on top of durable hardware, increasing customer lifetime value and strengthening margin durability. As adoption of connected devices grows, investors should expect a clearer mix of recurring revenue alongside product sales.
• Manufacturing capacity, solid gross margins, and a strengthened balance sheet give the company room to grow without heavy capital pressure. The key drivers to watch are execution milestones like broader payer coverage, uptake of smart devices within the installed base, and steady progress toward visible recurring revenue. If those pieces fall into place, the story increasingly becomes one of scale and sustainability rather than proof.

Upcoming: Scottsdale Capital Event

April 10–12, 2026

Set in the Arizona desert, the 13th Annual Scottsdale Capital Event brings CEM’s relationship-driven format back this spring, pairing high-quality growth companies with capital that is actively looking for opportunity. In this setting, growth-stage companies across resources, technology, biotech, and special situations engage capital directly through a full day of scheduled one-on-one meetings and focused networking.

Warm Regards and Happy Investing,
Fabian Dawson

Weekly Insight

Each week, CEM Partner and Portfolio Manager Ryan Iverson spotlights the ideas and companies sparking investor interest from emerging growth stories to the Top Picks featured across CEM’s Capital Events. This series brings real insights from the innovators shaping tomorrow’s markets and reveals where investors are finding the next breakout opportunities.

Stay informed. Stay ahead. Stay with the Investor Breakout Exchange:
X | Facebook | LinkedIn | Instagram | YouTube | TikTok